|
|
|
|
|
|
|
involved in drug development, including pharmacology, chemistry, biotechnology, pharmacokinetics, metabolism, regulatory affairs, pharmaceutics, marketing, and, of course, management, again with the charge of challenging the present system and suggesting alternatives. Our intention has been to describe different potential approaches for those engaged in the difficult and regulation-bound drug development process. If we have sown some seeds and increased the reader's awareness of the challenges to be met and opportunities to be grasped, then we have succeeded in our task. |
|
|
|
|
|
|
|
|
We wish to thank the contributing authors, who willingly took time away from busy schedules to contribute in their areas of specialization. We thank also our administrative colleagues who were responsible for preparing manuscripts. Particular thanks are due to Ms. Theresa Davis, who administratively kept the whole thing together and thereby made our tasks much easier. |
|
|
|
 |
|
|
|
|
PETER G. WELLING
LOUIS LASAGNA
UMESH V. BANAKAR |
|
|
|
|
|